Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 7/18/23 → 7/18/25 |
Funding
- Lisata Therapeutics Incorporated: $57,816.00
23-MULTI-59-LTI(LTSA1-P02): A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects with Advanced Solid Tumors (BOLSTER)
- Arnold, Susanne (PI)